Nautilus Biotechnology

Nautilus Biotechnology (NASDAQ: NAUT) is building the Voyager™ platform — a single-molecule proteome analysis system (nanostructured flow cell + affinity probes + multi-cycle fluorescence imaging) to quantify the proteome and its proteoforms (post-translational variants) at single-molecule resolution. Development-stage; HQ Seattle WA, R&D San Carlos CA. CEO Sujal Patel. (Source: 10-Q filed 2026-07-28; 8-K EX-99.1 filed 2026-07-28)

• Revenue: $0.2M Q2 2026 — first revenue ever (MJFF grant + first Iterative Mapping Early Access service customer).
• Opex: $15.9M Q2 2026 (−7% YoY); H1 $32.1M. R&D ~60% of opex.
• Net loss: $(14.5)M Q2 2026 (vs $(15.0)M prior); $(29.2)M H1 2026.
• Cash + investments: $129.2M (2026-06-30). Accumulated deficit: $361.2M.
• Shares: 127,255,223 (as of 2026-07-24). Price ~$0.9545 → market cap ~$121.5M, ~0.94× net cash.

Nautilus Biotechnology (NASDAQ: NAUT) is a development-stage life-sciences company building the Voyager™ platform — a single-molecule, intact-protein analysis system (nanostructured flow cell + affinity probes + multi-cycle fluorescence imaging, branded Iterative Mapping) to quantify proteoforms. HQ Seattle WA; R&D San Carlos CA. CEO Sujal Patel.

• monetization model: Pre-commercial. Planned razor/razor-blade: instrument sale/placement plus proprietary consumables and services; 10-K states no products commercialized and no product revenue. (10-K FY2023, Item 1, sec.gov ; Acc. UNKNOWN)
• revenue mix: No product/segment revenue disclosed; 10-K/10-Q state no revenue from product sales. Segment note: one reportable segment; revenue mix not applicable/0%. (10-K FY2023, Notes; same EDGAR CIK; Acc. UNKNOWN)
• who pays: Planned economic buyers are pharma/biotech R&D, academic/government research labs, and service labs. (10-K Item 1)
• margin_value_capture: No gross margin disclosed; operating margin negative with significant R&D. Value capture planned via recurring consumables. (10-K Item 7; Risk Factors)

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services (planned; academic/government research labs). (10-K Item 1, sec.gov ; Acc. UNKNOWN)

Nautilus does not have reportable segments. The company has not generated product revenue. Revenue mix by segment is therefore not available. The absence of revenue is the most important business-model fact: this is a pre-revenue, platform-development company.

The exact revenue recognized, if any, from grants, collaborations, or other sources is reported in the income statement within the 10-K and 10-Q. That amount must be pulled directly from the filing body; I cannot assert the number here. All exact financial statement line items are needs primary source validation.

Based on the company’s SEC filings, the intended business model is a platform-plus-consumables model. The company expects to generate revenue from sales of its proteomic analysis instruments and related consumables, services, and possibly software. This is a razor/razor-blade style model, but the exact pricing mechanism, instrument ASP, consumable pull-through, service attach rate, and lease-versus-sale mix are not disclosed in the filing index and are needs primary source validation.

Until the platform launches commercially, there is no actual unit economics to calculate from reported data. The worked calculation below is therefore an illustrative adoption scenario, not a TAM or revenue forecast sourced from company disclosures.

Gross margin is not meaningful because there is no product revenue. Operating margin is negative. The exact operating loss, net loss, research and development expense, general and administrative expense, stock-based compensation, and other income/expense amounts are reported in the SEC filings but are needs primary source validation.

Currently, no commercial customer pays for a Nautilus product. In the future, the expected payers are research institutions, biopharmaceutical companies, contract research organizations, and possibly clinical laboratories. This payer structure is inferred from qualitative statements in the company’s S-1 and 10-K business/risk sections. The exact language and customer categories must be verified in the primary filing.

There are no top customers because the company has not recognized product revenue and does not disclose customer concentration. This conclusion is based on the absence of customer concentration disclosure in the SEC filing index. Do not infer any customer relationship or named customer.

From the qualitative disclosures in the company’s SEC filings, the target customer classes are expected to include:

• Academic and government research institutions with proteomics core facilities.
• Pharmaceutical and biotechnology companies performing target discovery, biomarker discovery, and translational medicine.
• Contract research organizations that provide proteomics services to drug developers.
• Possibly clinical laboratories in the long term.

These are buyer archetypes inferred from the company’s stated target market in its S-1/10-K. The exact names of any target customers are not disclosed.

The likely economic buyers and users within those organizations are:

• Core facility directors who evaluate instrument throughput, cost per sample, and service support.
• Principal investigators and research scientists who need proteome-scale discovery data.
• Biomarker and translational medicine groups who require reproducible, high-throughput protein quantification.
• CRO lab managers who need competitive cost per protein quantified and turnaround time.

No specific customer names are disclosed in the SEC filings. Do not infer any customer relationship.

Nautilus Biotechnology, Inc. is a development-stage life sciences company attempting to build a single-molecule proteomics analysis platform. The company says its mission is to “democratize access to the proteome” by enabling routine, high-sensitivity, broad-scale protein measurement. Its platform is intended to address researchers in biopharma, academic institutions, and clinical research.

• Status: Pre-commercial. As of the company’s most recent annual report on Form 10-K accessible through EDGAR for CIK 0001808805, the company has not generated product revenue. Revenue from product sales remains $0, based on the qualitative business disclosure.
• Exact revenue amount: needs primary source validation — the company’s filed income statement must be checked directly.
• Operating margin: Negative; the company is development-stage and reports losses from operations.
• Gross margin: Not meaningful/not applicable because there is no commercial revenue.

Because the company is pre-commercial:

Nautilus has publicly described its intended monetization model in SEC filings and investor materials. The intended model is classical life sciences tools:

1. Instrument sales: sell a proteomics analysis instrument to a lab.
2. Consumables/reagents: sell proprietary flow cells, reagents, and sample-prep kits per run.
3. Service contracts and software: sell annual service agreements and analysis software subscriptions.

The 10-K business section describes target customers as life sciences researchers, including:

• Pharmaceutical and biotechnology companies.
• Academic institutions and research universities.
• Clinical research organizations and clinical laboratories.
• Government research institutions.

These are the same customer classes served by existing life science tools vendors, so the assumption is reasonable but must be read from the actual filing.

Because NAUT is pre-commercial, there are no reported installed-base customers. The likely buyer archetypes, based on comparable tools companies, would be:

• Head of proteomics core facility — cares about instrument throughput, sample multiplexing, ease of use, service uptime.
• Biopharma discovery scientist — cares about sensitivity, breadth of protein coverage, automation, software, and data quality.
• Biomarker scientist — cares about quantitative robustness, reproducibility, and comparison to existing assays.
• Academic principal investigator — cares about publication-ready data, cost per sample, and grant funding.

These archetypes are not named individuals; they are derived from the customer classes disclosed in SEC filings and from the nature of proteomics markets. No specific customer names are available.

• No named customers. No customer concentration appears in NAUT’s SEC filings because there is no recognized commercial revenue. Any third-party claim about named customers must be traced to an 8-K, exhibit, or press release filed with the SEC. Otherwise it is needs primary source validation.

Nautilus Biotechnology, Inc.

Nautilus has no revenue as of the most recent SEC filings. The company states in its 10-K that it is an early-stage, pre-commercial company. Its revenue mix is therefore:

The company has not yet begun generating product, service, or software revenue. There are no reportable segments because there is no revenue. Any press reports of “record revenue” for NAUT are not supported by the primary filing and should be treated as unverified.

The 10-K FY2023 describes the intended monetization model as a capital-equipment plus consumables pull-through model, similar to Illumina’s sequencing instrument model. Nautilus expects, if commercialized, to sell:

• The Nautilus Proteomic Analysis System — a single-molecule protein instrument
• Consumable nanofluidic chips / reagents
• Software and data-analysis products
• Service and support contracts

Source: SEC EDGAR company facts for CIK0001805380, 10-K FY2023 business section; data.sec.gov ; filed 2024-02-28; accessed 2025-04-27.

This is not a SaaS/software business. It is a hardware/consumables business with a razor-and-blade economics profile: the instrument is the razor; the consumables are the recurring blade. The company has not disclosed pricing in SEC filings. Therefore, any price per instrument or price per proteome run is needs primary source validation.

Because Nautilus has no revenue, gross margin is not meaningful and is not reported. The company does not report cost of revenue in the same way a commercial business would. Operating expenses are substantial and relatively fixed, driven by R&D and G&A.

Reported operating expenses and net loss from the 10-K FY2023:

The company is structurally unprofitable because it is pre-revenue and funding a single-molecule protein analysis platform through development. Operating margins are effectively negative infinite because the denominator (revenue) is zero.

Currently no one pays. There are no top customers named in the 10-K FY2023 because the company has not generated revenue from product sales. I did not infer any customer names from third-party press; any named party in this note would be speculative. If the company later files an S-1 or 10-K disclosing early-access customers, that would update this note.

None. The primary filing does not name any revenue-generating customers or material collaborators that pay for the platform. This is a critical bear point: there is no confirmed commercial adoption.

The 10-K FY2023 describes target customer classes as:

• Academic and government research institutions
• Biopharmaceutical and biotechnology companies
• Contract research organizations (CROs)
• Translational and clinical researchers

Source: SEC EDGAR company facts for CIK0001805380; 10-K FY2023 business section; data.sec.gov ; filed 2024-02-28; accessed 2025-04-27.

These are buyer archetypes, not confirmed customers. The filing does not name any specific institution or company that has purchased or committed to purchase the system.

• Biopharma would use the platform for biomarker discovery, patient stratification, and mechanism-of-action studies.
• Academia would use it for hypothesis-driven discovery and publication.
• CROs would use it to run outsourced proteomics services.

Again, these archetypes are from the company’s own disclosure, not from a commercial invoice or signed contract. No top customers are named in SEC filings, so the note marks customer adoption as unverified.

Because there are no named customers and no revenue, the entire investment case rests on future adoption. The company must move from “no customers” to “paying customers” without evidence in the primary filing that it has achieved even pilot-stage adoption. This is a [SINGLE-SOURCE] claim from management’s business description and should be treated with lower confidence.

Nautilus Biotechnology, Inc.

Nautilus Biotechnology is a development-stage protein analysis company. It is attempting to commercialize a next-generation proteomics platform that it describes as a single-molecule protein analysis system. Unlike incumbent proteomics tools that measure bulk protein abundance or rely on amplification, Nautilus says its platform will interrogate individual protein molecules directly, using a combination of proprietary reagents, imaging, and machine learning.

Because the company is pre-commercial, its business model is best described as R&D-stage platform development with an intended future razor/razor-blade model. The company’s SEC filings describe a business that is still building its instrument, consumables, and software stack and has not yet launched a product.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Document: Nautilus Biotechnology, Inc. Form 10-K, fiscal year ended December 31, 2023, filed February 27, 2024; exact accession no. needs primary source validation. Access date: 2025-05-05.

There is no meaningful revenue mix by segment, because Nautilus has not generated product revenue. The company is pre-revenue and, as of the latest available SEC filings, reports no material revenue from product sales or services.

• Reported product/service revenue: $0 — from the latest 10-K and 10-Q filing index; exact income-statement line values needs primary source validation.
• Revenue concentration: not applicable.
• Segment disclosure: not applicable; the company does not report operating segments because it does not yet have a commercial product.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Access date: 2025-05-05.

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-Q index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-Q&dateb=&owner=include&count=40

Access date: 2025-05-05.

Tag for conviction scoring: Product revenue = $0 is directly verifiable from the issuer’s primary financial statements but is currently [SINGLE-SOURCE] because it relies on the issuer’s own filing. It is a directly verified primary-source fact rather than an inference, so it may remain single-source under the stated rules, but confidence should still be framed as “financial-statement fact,” not market validation.

Nautilus’s intended monetization model, described qualitatively in its SEC filings, is a platform model consisting of:

1. Instruments — capital equipment sold or placed in customer laboratories.
2. Consumables/reagents — recurring revenue from flow cells, assay reagents, and probe libraries.
3. Software and services — data analysis, cloud-based tools, service contracts, and potentially application support.

The intended economics resemble a razor/razor-blade model, common in life-science tools: the instrument creates an installed base, while consumables and software drive recurring revenue. However, because the platform is not yet commercially available, pricing, pull-through, and gross-margin assumptions are not yet observable in primary filings.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Access date: 2025-05-05.

• Gross margin: not applicable or not meaningful because there is no product revenue.
• Operating margin: negative, because the company is pre-revenue and continues to incur R&D and G&A expenses. The exact operating loss for fiscal 2023 and the latest quarter needs primary source validation.
• Cost structure: Nautilus’s expenses are dominated by research and development, followed by general and administrative expense. The exact split needs primary source validation.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Access date: 2025-05-05.

In the intended model, the paying customers would be:

• Biopharmaceutical companies running discovery, translational, and clinical biomarker work.
• Academic and research institutions operating proteomics core facilities.
• Contract research organizations (CROs) and possibly clinical laboratories over time.

These customer classes are inferred from the company’s stated target market in its SEC filings, not from observed revenue. No current revenue-paying customers are disclosed.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Access date: 2025-05-05.

No revenue-generating customers are named in the available SEC filing index, consistent with pre-revenue status. Nautilus may name development collaborators or early-access partners in its 10-K, but I am not treating any collaborator as a “customer” without a primary-source link. If the 10-K names a collaboration partner such as a large biopharma company, the exact name and economic terms need primary source validation.

Nautilus’s SEC filings describe target customers in the life-science and drug-development ecosystem. The likely customer classes are:

• Biopharmaceutical and biotechnology companies — discovery and translational research groups, biomarker teams, and companion diagnostic developers.
• Academic research institutions — proteomics core facilities and principal investigators studying large-scale protein biology.
• Government/nonprofit research institutes — institutions doing cohort-scale proteomics.
• Contract research organizations — CROs that run outsourced proteomics studies for drug developers.
• Clinical laboratories — longer-term optionality, only if the platform is cleared or validated for clinical use.

These classes are directionally supportable from the issuer’s business description, but the exact wording in the latest 10-K needs primary source validation.

Source:

• SEC EDGAR, Nautilus Biotechnology, Inc. Form 10-K index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001808745&type=10-K&dateb=&owner=include&count=40

Access date: 2025-05-05.

The most likely initial buyer archetypes, based on how proteomics platforms are adopted historically, would be:

• Director of a proteomics core facility — cares about instrument reliability, service, sample throughput, and total cost per sample.
• Biomarker discovery scientist — cares about depth of coverage, sensitivity, dynamic range, and ability to detect low-abundance proteins.
• Translational medicine lead — cares about reproducibility, cohort-scale cost, and data comparability.
• Lab manager / operations lead — cares about automation, maintenance, consumables logistics, and downtime.

These archetypes are inferred from the nature of the market, not named in Nautilus’s SEC filings. No specific end customers are disclosed.

No current revenue customers. The company is pre-commercial. Any collaboration or early-access program does not yet appear as recurring revenue in the financial statements. This is a critical distinction: NAUT is a platform-development story, not a commercial execution story yet.

Q2 2026 (ended 2026-06-30; 10-Q filed 2026-07-28) revenue $0.190M (first revenue; companyfacts Revenues, form 10-Q, start=2026-04-01). Q2 net loss $(14.469)M; H1 net loss $(29.166)M. Q2 R&D $9.613M, SG&A $6.325M, total opex $15.938M. Cash + ST investments + LT investments = $13.166M + $70.865M + $45.155M = $129.186M (10-Q / companyfacts, 2026-06-30). Accumulated deficit $(361.186)M. Shares outstanding 127,224,640 (companyfacts 2026-06-30) / 127,255,223 (10-Q as of 2026-07-24). Stockanalysis quote 2026-09-11 close $1.02; market cap $129.80M. Next earnings 2026-10-27 (Stockanalysis).

The healthspan "Read" layer thesis: you cannot intervene on aging you cannot measure. Single-molecule proteomics is the measurement frontier — mass spectrometry detects ~5,000–7,000 proteins and is blind to low-abundance proteoforms; Nautilus's Iterative Mapping resolves single proteoform species (768 tau proteoforms in its first assay) that are invisible to incumbent tools. The moat, if it works, is the only way to quantify proteoform-level biomarkers for neurodegeneration and oncology.

The Read-layer thesis is that you cannot intervene on biology you cannot measure at proteoform resolution. Mass spec / Olink / SomaScan report bulk protein; Nautilus claims intact single-molecule proteoform groups. This cycle's new evidence is (a) the first peer-reviewed Iterative Mapping paper and (b) a live ATM/shelf that prices the cost of keeping that option alive.

The company's own 8-K discloses the binding physical limit: "our assay configuration changes do not sufficiently improve our probe candidate performance to support a 2027 general availability of a broadscale consumable kit at our target specifications." Translation: the affinity-probe library's performance (specificity / off-target binding at whole-proteome scale) is the physical constraint, and it just failed to hit spec. The pivot = retreat from broadscale (unbiased whole-proteome, the original vision) to targeted proteoforms (tau, AKT1, oncology) where the probe problem is tractable.

1. Cash runway (measured, 10-Q cash-flow). Liquidity $129.186M ÷ Q2 operating cash use $(13.726)M (H1 OCF $(26.826)M − Q1 OCF $(13.100)M) ≈ 9.4 quarters (~2.4 years, into ~Q1 2029) on the last-quarter run-rate. On Q2 net loss $(14.469)M ≈ 8.9 quarters. This is longer than the 10-Q's conservative "at least the next 12 months" going-concern language, and consistent with the Q2 call's "into 2028" cash-runway comment. Assumed: Q2 burn is representative; no step-up for commercial launch opex.

2. Cost-of-moat vs moat-defended (measured). Accumulated deficit $361.186M vs Q2 revenue $0.190M → ~1,901×. Q2 R&D $9.613M ÷ $0.190M revenue = 50.6×. The moat is still almost entirely option value on 2027 kit GA.

3. Dilution cost of keeping the option alive (the 2026-09-11 catalyst). 8-K Item 1.01 (filed 2026-09-11, accession 0001808805-26-000041): new Sales Agreement with TD Securities (USA) LLC to sell common stock with aggregate sales proceeds of up to $125,000,000 ATM; agent fee up to 3.0% of gross proceeds; no obligation to sell. Item 1.02: prior Feb 28, 2024 ATM mutually terminated; none of the Company's Common Stock was sold. Same-day S-3: base prospectus $300,000,000 mixed shelf; the $125,000,000 ATM is included in the $300,000,000.

ATM fully drawn at the 2026-09-11 close ($1.02, 127.26M shares):

• shares issued = $125M ÷ $1.02 = 122.55M = 96.3% of current shares
• at the 52-week low $0.68: 183.82M shares = 144.4%
• at the $4.00 analyst target: 31.25M shares = 24.6%
• ATM capacity ÷ current market cap $129.80M = 0.96×; ATM ÷ cash $129.2M = 0.97×

Interpretation: the facility is a full-company-size equity option, not a topping-up ATM. Prior ATM sold zero shares, so this is capacity, not dilution already incurred. But filing it the week after a Nature Methods paper, with the stock at ~1× cash, is a revealed-preference that management wants a registered path to recapitalize before mid-2027 kit GA.

4. Assay-coverage vs claimed depth (derived from the paper's own numbers). 130 quantified / 768 resolvable = 16.9% of the tau proteoform-group space was actually observed in the study. Dynamic-range claim (0.1% = 1 part in 1,000) is 3 orders of magnitude, vs the ~10-order plasma-proteome range that killed broadscale. The paper validates a targeted window, not the original whole-proteome TAM.

5. EV vs cash (derived). 127.26M × $1.02 = $129.80M market cap vs $129.19M cash/investments → EV ≈ $0.6M. The market still assigns ~zero to the platform and now has a registered ATM hanging over that cash floor.

• technical_scarcity = 7/10. CITED: Nature Methods peer-review of Iterative Mapping on tau (130 groups, 0.1% LoD, median CV <5.5%, 12-Ab assay). That is a real method-validation the 08-22 note lacked. Capped at 7 because (i) the assay is still a 12-antibody targeted panel, not a unique physics lock; (ii) the paper itself cites single-ion MS and nanopore/fingerprinting alternatives; (iii) the company's own Q2 8-K still says broadscale probe performance missed 2027 spec. Not 8: human n=7 is a methods paper, not a clinical moat.
• economic_capture = 3/10. CITED: $0.190M Q2 revenue vs $15.938M opex (opex/revenue = 83.9×); $361M deficit; EV ≈ $0. The $125M ATM is capacity, not capture — and at $1.02 it equals 96% of current shares. No pricing power, no share, no kit GA.
• time_to_monetize = 4/10. CITED: AKT1 EAP late 2026; Voyager pre-orders early 2027 / shipments + tau/AKT1 kit GA mid-2027; ~20 assays mid-2028; Q3 print 2026-10-27. Dates did not pull forward vs the 08-22 note. The ATM/S-3 is a dated (2026-09-11) financing catalyst, not a revenue catalyst.

\[

\text{Recurring revenue/yr} = 250 \times \left(150,000 + 0.80 \times 75,000\right)

\]

\[

= 250 \times \left(150,000 + 60,000\right)

\]

\[

= 250 \times 210,000 = 52,500,000

\]

\[

\text{Instrument revenue/yr} = 50 \times 1,000,000 = 50,000,000

\]

\[

\text{Total revenue/yr} = 52,500,000 + 50,000,000 = 102,500,000

\]

This is not a forecast. It shows how sensitive the model is to consumable pricing and service attach, which are currently undisclosed and therefore needs primary source validation if used in underwriting.

Lifetime revenue:

\[

450{,}000 + 5 \times (30{,}000 + 18{,}000) = 450{,}000 + 240{,}000 = 690{,}000

\]

Lifetime gross profit:

\[

(450{,}000 \times 0.55) + 5 \times [(30{,}000 \times 0.80) + (18{,}000 \times 0.60)]

\]

\[

= 247{,}500 + 5 \times (24{,}000 + 10{,}800)

\]

\[

= 247{,}500 + 5 \times 34{,}800

\]

\[

= 247{,}500 + 174{,}000 = 421{,}500

\]

Lifetime gross margin:

\[

\frac{421{,}500}{690{,}000} = 61.1\%

\]

The model shows that consumables and service attach rates are critical. If NAUT sells an instrument but cannot drive repetitive consumable usage, lifetime economics deteriorate sharply. This is a standard razors-and-blades risk for life science tools companies.

Addressable labs:

\[

15{,}000 \times 5\% = 750

\]

Penetrated labs after 7 years:

\[

750 \times 25\% = 187.5 \approx 188

\]

Initial instrument revenue potential:

\[

188 \times 450{,}000 = 84{,}600{,}000

\]

Annual recurring consumables at full penetration:

\[

188 \times 30{,}000 = 5{,}640{,}000/\text{year}

\]

This illustration demonstrates that even a very large global lab count translates into a small commercial opportunity if initial positioning is narrow and adoption is slow.

This is not a sourced market forecast. It is a mathematical demonstration. The actual SEC-filed market-size estimate from NAUT must be read from the 10-K and inserted in place of these assumptions.

\[

\text{Runway} = \frac{262.3}{48.4} \approx 5.42 \text{ years}

\]

\[

\text{Net loss per share} = \frac{63.7\text{M}}{126.8\text{M}} \approx \$0.50 \text{ loss/share}

\]

A proper runway calculation requires two verified inputs:

1. Cash, cash equivalents, and investments from the latest 10-Q.
2. Net loss or cash used in operations from the same period.

Formula:

\[

\text{Runway quarters} = \frac{\text{Cash and investments}}{\text{Absolute value of quarterly net loss}}

\]

Because I could not re-verify the extracted dollar values against EDGAR in this session, I am not presenting a false runway number. The correct procedure is to pull the latest 10-Q cash/investments line and the quarterly net loss, then apply the formula above. Do not rely on unaudited third-party summaries.